

VIA DHL EXPRESS



May 1, 2008

Cody C. Wiberg
Executive Director,
Minnesota Board of Pharmacy
2829 University Avenue S.E., #530
Minneapolis, MN 55414-3251

GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709-3398
Tel. 919 483 2100
www.gsk.com

Dear Mr. Wiberg:

Pursuant to applicable Minnesota state law, SmithKline Beecham Corporation d/b/a GlaxoSmithKline ("GSK") submits to the Minnesota Board of Pharmacy GSK's 2007 report of its payments, reimbursements or other compensation paid to individual practitioners. The attached report reflects payments made by GSK to Minnesota practitioners for consulting services and services provided in connection with educational programs. Please note that on December 18, 2007, GSK acquired Reliant Pharmaceuticals ("Reliant"). Reliant will submit its report for the period January 1, 2007 through December 31, 2007 under separate cover. Future reports will be submitted under one cover.

GSK has arrangements with foundations, universities, contract research organizations and other business entities to conduct research or provide information under which payments may be made by such institutions to Minnesota practitioners. Compensation to Minnesota practitioner in these cases is not from GSK; therefore, payments to these entities are not reflected on the attached report. Similarly, the report does not state payments to sponsors of independent medical conferences, continuing medical education programs, professional meetings or other educational programs, where GSK may provide funds through a grant to an organization, but does not pay a practitioner (e.g., educational grants).

Although the Minnesota law states that the reports are public data, GSK considers the information in this report to be confidential and propriety information. GSK does not publicly release this information or the company documents that were used to create this report. Further, release of the entries in this report or the aggregate information in this report may give GSK's competitors information that may undermine its relationship with its contractors and consultants and enable competitors to gain a business advantage.

If the Minnesota Board of Pharmacy has any questions regarding this letter or the information contained in our report, please contact Michelle West at 215-751-6526.

Sincerely,

A handwritten signature in black ink, appearing to read "Arjun Rajaratnam".

Arjun Rajaratnam,
Vice President & Compliance Officer U.S. Pharmaceuticals